SB161 would require that non-opioid pain treatments that have FDA approval be included on this preferred drug list with coverage terms that are no more restrictive than those given to opioid pain ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...

Tracking disability policies has long been challenging − this will become a harder task under the Trump administration.

A groundbreaking national poll conducted on behalf of the Diabetes Patient Advocacy Coalition (DPAC) reveals overwhelming ...

The Coalition to Strengthen America's Healthcare today launched a new national advertising campaign highlighting Medicaid's impact on the more than 72 million Americans who rely on the program for ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and ...

The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, which was accepted by ...

Legislators may launch a study of how weight loss drugs might reduce costs in the Iowa Medicaid program. Jeffrey Boeyink is a ...

Through the Arkansas Opioid Recovery Partnership, we have funded innovative programs aimed to slow the relentless increase in ...

Limiting mifepristone access, changing Title X rules and implementation of the Emergency Medical Treatment and Labor Act are ...

House Democrats are ramping up their attacks on the GOP’s budget plan, warning that the massive spending blueprint would ...

Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...